We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Seegene Reveals New Real-Time PCR at AACC 2014

By LabMedica International staff writers
Posted on 29 Jul 2014
Seegene Inc. More...
(Eschborn, Germany), a developer of multiplex PCR technologies, revealed their “MuDT” technology at the AACC 2014 meeting. MuDT is a real-time polymerase chain reaction (PCR) technology that will cause a shift in the PCR instrument market. The technology doubles the multiplexing capacity of any existing real-time PCR instrument––thus maximizing the value of the installed base of these instruments.

MuDT technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware.

The biotechnology industry has relied on real-time PCR for at least 20 years a molecular diagnostics technology, because of its versatility, speed, and ease of use. Despite many attempts, the biotechnology industry has not made significant advances that satisfy the growing demand for increased multiplexing and target quantification using limited numbers of channels in a single tube. Even melt curve analysis, after amplification has many disadvantages, such as end-point analysis after amplification, extended turnaround time, lack of quantification, and melt temperature variation due to target sequence variations on probe binding regions.

Additional benefits of the technology include: easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification, SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel.

Seegene is a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics that can simultaneously detect multiple targets with sensitivity, specificity, and reproducibility. The company's products detect multipathogens with good reliability and throughput, ultimately providing an economical basis for saving time, labor, and cost.

Related Links:

Seegene 



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Laboratory Software
ArtelWare
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.